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Background/aim: Studies mostly focused on risk factors and clinical status in children with cerebral palsy (CP). Various antiinflammatory
markers may help us in the early diagnosis and clinical classification of cerebral palsy patients. In this study, the relationship between
antiinflammatory marker levels and clinical status in patients with CP is determined. It is the first time that Fetuin-A and Paraoxonase-1
(PON-1) are examined in children with CP.
Materials and methods: The study is conducted on 79 children which are divided into two groups as CP and control. Gross motor
function and spasticity are evaluated in addition to biochemical parameters.
Results: There is a statistically significant difference between CP and control group in terms of PON-1 activity, high sensitive C-Reactive
Protein, HDL, and total cholesterol levels. There is no statistically significant difference in Fetuin A levels between the two groups.
Conclusion: In suspected CP patients less than 24 months of age who possess prenatal and postnatal risk factors, the determination of
PON-1 activity can be considered as a biomarker to support early diagnosis.
Key words: Fetuin-A, paraoxanase-1, cerebral palsy, children

1. Introduction
Cerebral palsy (CP) is a state of encephalopathy characterized
by nonprogressive posture and motor impairment, usually
accompanied by speech abnormalities, visual and cognitive
defects, and epilepsy resulting from injury to the developing
brain that occurs antenatally, perinatally, or early
postnatally [1–3]. The incidence of CP is approximately 1.5
to 2.5 per 1000 live births worldwide, whereas in Turkey
is 4.4 per 1000 live births [4,5]. Several factors play a role
in the etiology of CP which partly explains variations in
clinical findings. It may be due to either congenital, genetic,
inflammatory, metabolic, anoxic, traumatic, or infectious
causes [6]. Hypoxic-ischemic and inflammatory conditions
are among the key factors which lead to cell death and
cell process loss in CP patients [3]. An antioxidant and
antiinflammatory enzyme known as Paraoxonase 1 (PON1) a member of the paraoxonase family which is primarily
expressed in the liver, is transported in the circulation
via high-density lipoprotein (HDL). It is well known that
PON-1 prevents further damage with its peroxidase and
lactonase activity during the inflammatory process and

in this way provides antioxidant and antiinflammatory
actions. Changes in circulating PON-1 concentrations
are reported in certain diseases like cardiovascular and
neurological diseases in which oxidative stress is involved
[7,8]. Another antiinflammatory marker, Fetuin-A has a
glycoprotein structure and it belongs to the cystatin protein
family which is mainly synthesized in the liver. Fetuin-A
shows neuroprotective effect by its antiinflammatory
effect in cerebral ischemia. It is known that Fetuin-A
plays a role in the remodeling of the neonatal brain and
it is reactivated in the damaged brain [9,10]. Therefore,
increased Fetuin-A level may reduce the inflammatory
response and prevent further brain damage [11]. Cerebral
palsy patients can be clinically assessed by the gross motor
function classification system (GMFCS) which is the gold
standard for evaluating motor function in CP patients [12].
Moreover, fine motor function test and modified Ashworth
scale are also generally used in this group to determine the
degree of spasticity [13].
To date, studies have focused on risk factors and clinical
status in children with CP. According to our knowledge,
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there is no study evaluating antiinflammatory markers like
PON-1 activity and Fetuin-A levels and clinical status. In
our study, we aimed to investigate the relationship between
antiinflammatory markers such as PON-1, Fetuin- A, high
sensitive C-Reactive Protein (hsCRP) as well as blood lipid
parameters and clinical status in patients with CP.

frequency, percentage, median, quartiles) and also
quantitative data that did not show normal distribution
were used for the Mann-Whitney U test. Pearson chisquare test and Continuity (Yates) corrected chi-square
tests were used to evaluate the qualitative data. Significance
was accepted as p < 0.05.

2. Materials and methods
2.1. Study design
The patients with cerebral palsy were admitted to the
physical therapy and rehabilitation unit in the Göztepe
Medical Park Hospital. The study was conducted with 79
children which were divided into two groups as CP (n =
38) and control (n = 41). The patient’s history was taken
and a physical examination was performed. The control
group was selected from healthy children outpatient
clinic. Age, sex, and other demographic characteristics of
the control group were matched accordingly with the CP
group. Children with epilepsy, head trauma, any kind of
neuropsychiatric disorder and metabolic disorder, acute
or chronic infection were excluded from the control
group. The study protocol was approved by the local ethics
committee and written informed consent for the study was
obtained from the legal guardian of all subjects.
2.2. Assessment of gross motor function and spasticity
The Modified Ashworth scale (MAS) was used to determine
spasticity. The total score was obtained from the addition
of individual scores of hip, knee, and ankle for both lower
limbs. Gross motor functional ability was evaluated by the
GMFM-66 [14,15].
2.3. Biochemical analysis
After overnight fasting, blood was collected. Serum was
separated using centrifugation at 1500 × g for ten min.
Serum samples were aliquoted and stored at –80 °C until
analysis. High sensitivity CRP (hsCRP), total cholesterol,
LDL (low-density lipoprotein), triglyceride, and HDL
(high-density lipoprotein) levels were determined by
Abbott Architect ci8200 autoanalyzer (Abbott Park, IL,
USA). Paraoxonase activity was measured by the initial
rate of paraoxon hydrolysis to yield pnitrophenol at 25 °C
with spectrophotometric technique which was performed
at 405 nm [16]. Fetuin-A level was evaluated by using
enzyme-linked immunosorbent assay (ELISA) Aviscera
Bioscience (Santa Clara, California, USA) according to
the manufacturer’s instructions. Intra- and inter assay
coefficients of variation were found to be 4.5%.
2.4. Statistical analysis
In this study, IBM SPSS Statistics 22 for statistical analysis
(SPSS IBM, Turkey) programs were used. The suitability
of the variables to normal distribution was evaluated
by Shapiro Wilks test, Q-Q graphs, and histograms.
Descriptive statistical methods (mean, standard deviation,

3. Results
We included 79 children and 38 of them were CP whereas
41 were in the control group in our study. The general
characteristics of study groups are shown in Table 1.
The clinical findings of CP group were evaluated by
physiatrists. Moreover, physical examination findings
of children in the CP group in terms of gross motor
function, fine motor function, modified Ashworth scale,
and reflex grades are represented in Table 2. Most of the
patients had GMF of Grade 3-5. The assessment of fine
motor function of our study group was mostly Grade 1.
Since the groups based on grades were not homogenously
distributed, we did not perform statistical analysis. When
we evaluated the biochemical parameters we found a
statistically significant difference between the CP and the
control group in terms of PON-1 activity, hsCRP, HDL,
and total cholesterol levels. Biochemical test results are
presented in Table 3. There was no statistically significant
difference in Fetuin-A levels between the two groups.
However Fetuin-A levels were significantly higher in
CP children without maternal intrauterine infection (p
= 0.043, p < 0.05), in children without congenital brain
malformations (p = 0.012, p < 0.05), in patients without
bradycardia and hypoxia in perinatal period (p = 0.036, p
< 0.05), in patients without mental retardation (p = 0.020,
p < 0.05), in patients without salivation (p = 0.012, p <
0.05), in patients without speech problems (p = 0.032, p <
0.05), in patients without musculoskeletal disorders (p =
0.002, p < 0.05) when compared to CP children with these
problems. On the other hand, Fetuin-A, LDL, and total
cholesterol levels were significantly higher in children with
CP who were not affected by socio-economic factors than
those affected (p < 0.05). The distribution of risk factors,
perinatal and postnatal characteristics are summarized
respectively in Table 4-5.
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4. Discussion
This study shows that PON-1 activity is significantly
lower and hsCRP levels are higher in children with CP
when compared with the control group. PON-1 which
is incorporated into HDL structure prevents lipoprotein
oxidation via lipid peroxide hydrolysis in oxidized LDL
and HDL molecules [8,17]. It is also known that low
PON-1 activity is a risk factor for the development of
cardiovascular disease independently of HDL level [8,18].
We detected low PON-1 activity and increased HDL level in
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Table 1. Evaluation of general characteristics of children by groups.
CP group
(n = 38)

Control group
(n = 41)

Total
(n = 79)

Age (months)

Mean ± SD

84.2 ± 40.2

67.8 ± 61.5

75.7 ± 52.7

Sex

Female

13 (34.2%)

15 (36.6%)

28 (35.4%)

Male

25 (65.8%)

26 (63.4%)

51 (64.6%)

≤24 months

3 (8%)

5 (12.2%)

8 (10.1%)

25–72 months

14 (36.8%)

12 (29.3%)

26 (33%)

73–108 months

14 (36.8%)

11 (26.8%)

25 (31.6%)

≥109 months

7 (18.4%)

13 (31.7%)

20 (25.3%)

Age group

Min-Max: Minimum-Maximum, Mean ± SD: Mean ± Standard Deviation
Table 2. Distribution of physical examination results of children
in CP group (n = 38).

Gross motor function

Fine motor function

Ashworth scale (modified)

Reflexes

Grade

n (%)

0

1 (2.6%)

1

3 (7.7%)

2

4 (10.3%)

3

7 (17.9 %)

4

20 (51.2%)

5

4 (10.3%)

0

6 (15.8 %)

1

31 (81.6 %)

2

1 (2.6%)

0

5 (13.1 %)

1

9 (23.7%)

2

18 (47.4%)

3

6 (15.8%)

0

11 (29 %)

1

7 (18.4%)

2

19 (50%)

3

1 (2.6%)

children with cerebral palsy in our study group, which may
be a risk factor in advancing age. Therefore, determination
of PON-1 activity may play a role in the early diagnosis
of cerebral palsy and follow-up in long term may give
information about the tendency of cardiovascular diseases.
There are some studies done for the determination of
PON-1 activity in the pediatric population [19–21]. It is
shown that low levels of PON-1 enzyme are maintained
between 2 to 7 years of age [22–24]. In our study, most of
the children in both the CP and the control group were
older than 2 years of age.

Another routine laboratory test which is hsCRP is
regarded as a prognostic marker in cerebrovascular and
cardiovascular diseases in addition to its inflammatory
action [25–27]. There was a statistically significant increase
in hsCRP levels in CP when compared to the control
group. Pingel et al. found that CRP levels are 8 times higher
in children with CP when compared to healthy adults.
Furthermore, CRP indicates catabolism of muscle tissue
and it might play a role between poor muscle function and
systemic inflammation [28]. Moreover, Fetuin-A which
plays a role in the remodeling of newborn brain tissue is
reactivated in damaged brain tissue such as ischemia and
inflammation [9]. However, we did not find any significant
difference when we compared the two groups. According
to the studies, there is no definitive reference range of
Fetuin-A in infants and children. This may be partly
explained by differences in diet, physical activity, and
genetics [11]. As far as we know antiinflammatory markers
such as PON-1 and Fetuin-A levels are not determined in
children with CP.
Although many risk factors of CP were identified up
to now, half of the diagnosed patients did not have any
risk factors [29]. In our study, inherited diseases and
socioeconomic factors are encountered approximately in
one-third of the CP patients. We found increased levels of
Fetuin-A, LDL, and total cholesterol in CP patients who
were not affected by socioeconomic factors.
Besides the antiinflammatory markers, a blood lipid
profile was also determined. In some studies, it was
indicated that CP patients have more tendency towards
vascular diseases which can be explained by increased
inflammatory status and impaired blood lipid profile
[30–31]. We observed a significant difference in HDL and
total cholesterol levels whereas there was no difference
in LDL cholesterol levels between the two groups. Cece
et al. reported that there was no difference by means of
total cholesterol, LDL, HDL, and triglyceride levels in
children with CP and the control group [32]. Another
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Table 3. Evaluation of biochemical parameters of children by groups.
Biochemical parameters

CP group (n = 38)
Median (min-max)

Control group (n = 41)
Median (min-max)

p-value

PON1 (U/L)

102.20 (96–121.8)

133.4 (104.9–156.4)

p < 0.001*

Fetui-A (pg/mL)

984 (368–1258)

421 (278–649)

p = 0.082

HDL (mg/dL)

50 (31–68)

32 (9–76)

p = 0.002*

LDL (mg/dL)

88 (57–147)

79 (32–165)

p = 0.060

Total cholesterol (mg/dL)

165.5 (119–219)

127 (79–282)

p = 0.002*

hsCRP (mg/L)

0.48 (0.2–12.69)

1.12 (0.2–4.57)

p = 0.052

Triglyceride (mg/dL)

106 (54–270)

110 (36–502)

p = 0.851

Mann Whitney U Test * p < 0.05
Table 4. Distribution of risk factors for children in the CP group (n = 38).
CP Risk Factors

Yes
n (%)

Inherited diseases

12 (31.6)

Maternal intrauterine infections

8 (21.1)

Metabolic diseases of the mother

5 (13.2)

Intrauterine anoxia or decreased blood flow to the fetus

7 (18.4)

Rh mismatch-development of kernicterus as a result of AB0 and Rh mismatch

3 (7.9)

Exposure to radiation. teratogens in the first trimester

1 (2.6)

Chemical poisoning

2 (5.3)

Complicated pregnancy. bleeding

4 (10.5)

Congenital brain malformations

5 (13.2)

Socioeconomic factors

12 (31.6)

Reproductive insufficiency

3 (7.9)

Maternal mental retardations. convulsions

-

Multiple pregnancy

10 (26.3)

Abortion trials

10 (26.3)

Fetus posture disorders due to lack of amniotic fluid

2 (5.3)

Abdominal trauma

1 (2.6)

Prenatal cerebral hemorrhage

-

study conducted by McPhee P et al. found that LDL levels
were high in adult CP patients in relation to reference
range [33]. Specific biomarkers can be used to evaluate
the clinical course in CP patients. These patients are
characterized by observations of caregivers such as head
lag, inability to grasp, not sitting, etc. The diagnosis of
cerebral palsy is made by evaluating the neurological
findings along with the associated risk factors. Due to the
variations in clinical indicators, diagnosis of CP is often
delayed until 12–24 months of age. It is known that earlier
diagnosis of CP provides an opportunity for initiating
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therapies in a period when brain development is rapid and
neuroplasticity occurs [29,34].
GMFCS not only gives information about the motor
function of the patient at the present time but also predicts
long-term physical limitations considering that the patient
may need physical assistance or mobility equipment in the
future. GMFCS is a 5 level clinical classification system
and it is not an applicable test for children younger than
24 months [29,34]. In our study, we had only 3 patients
younger than 24 months of age. Noble et al. used a modified
Ashworth scale to evaluate the degree of spasticity which
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Table 5. Distribution of perinatal and postnatal characteristics in
CP group (n = 38).
Yes
n (%)
CP perinatal period
Premature < 36 weeks

18 (47.4)

Low birth weight (< 2500 g)

20 (52.6)

Difficult/intervention delivery

14 (36.8)

Abnormal arrival

2 (5.3)

Intracranial hemorrhage

1 (2.6)

Trauma

1 (2.6)

Infection

9 (23.7)

Bradycardia and hypoxia

11 (28.9)

Low APGAR score

11 (28.9)

Anoxia

10 (26.3)

CP postnatal period
Trauma

2 (5.3)

Infection

7 (18.4)

Intracranial hemorrhage

1 (2.6)

Coagulopathies

-

Convulsion

5 (13.2)

Hyperbilirubinemia

11 (28.9)

Arteriovenous malformations

-

Anoxia

1 (2.6)

Inflammatory-immunological causes

-

Intracranial pathologies

1 (2.6)

can also explain the correlation between spasticity and
gross motor function suggested by other studies [35]. In
our study, 51.2% of patients were grade 4 in GMFCS and
47.4% of patients were grade 2 in the modified Ashworth
scale. Because of the uneven distribution of patients
correlation between laboratory parameters and clinical
status could not be performed.
There are several limitations to our study. First of
all, we could not find any relation between laboratory
parameters and GMFCS, modified Ashworth scale
because of the small sample size and uneven distribution
of groups. Since Fetuin-A, is increased in CP patients,
there was no statistically significant difference so it would
be appropriate to investigate in more detail with increased
sample size by stabilizing biological variables such as diet
and exercise. Furthermore, studies can be focused on the
role of PON-1 in CP patients for predicting cardiovascular
and cerebrovascular events which may be observed later
in life span.
In suspected CP patients less than 24 months of age
who possess prenatal and postnatal risk factors, the
determination of PON-1 activity can be considered as a
biomarker to support early diagnosis.
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